文献速递脑血管病

高龄房颤患者卒中二级预防:抗凝治疗与否

To Treat or Not to Treat: Anticoagulants as Secondary Preventives to the Oldest Old With Atrial Fibrillation.
PubMed 文献 · Stroke · 2017-05-09

抗凝治疗与各年龄组复发性缺血性卒中减少相关,≥90岁组出血增加最明显但未抵消总体获益。

要点

  • 80岁以上房颤卒中患者抗凝治疗与复发性缺血性卒中减少相关。
  • ≥90岁组出血增加最明显,但未抵消抗凝总体获益。
  • 除年龄外,未发现其他心血管危险因素或合并症影响抗凝相关出血风险。

核心结论

  • 在本研究患者特征下,更多患者可接受抗凝治疗而不致出血占优。
  • ≥90岁患者出血增加稍多,但未影响该年龄层的总体结局。

研究设计与样本

  • 观察性研究,使用4个登记库(包括瑞典卒中登记Riksstroke)。
  • 随访缺血性或出血性卒中、其他出血或死亡。

主要发现

  • 抗凝治疗与所有年龄组复发性缺血性卒中减少相关。
  • 出血在≥90岁组增加最明显,但未抵消抗凝总体有益效应。
  • 除年龄外,未发现其他心血管危险因素或合并症影响抗凝相关出血风险。
  • 非抗凝药物未影响大出血发生率。

临床怎么用

  • 基于本研究患者特征,可考虑扩大抗凝治疗范围而不致出血占优。
  • ≥90岁患者抗凝时出血增加稍多,但总体结局仍可获益。

局限性

  • 原文未报告观察性研究的具体局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Anticoagulant treatment is effective for preventing recurrent ischemic strokes in patients who have atrial fibrillation. This benefit is paid by a small increase of hemorrhages. Anticoagulant-related hemorrhages seem to increase with age, but there are few studies showing whether the benefits of treatment persist in old age. METHODS: For this observational study, 4 different registers were used, among them Riksstroke, the Swedish Stroke Register. Patients who have had a recent ischemic stroke, were 80 to 100 years of age, and had atrial fibrillation, were included from 2006 through 2013. The patients were stratified into 3 age groups: 80 to 84, 85 to 89, and ≥90 years of age. Information on stroke severity, risk factors, drugs, and comorbidities was gathered from the registers. The patients were followed with respect to ischemic or hemorrhagic stroke, other hemorrhages, or death. RESULTS: Of all 23 356 patients with atrial fibrillation, 6361 (27%) used anticoagulants after an ischemic stroke. Anticoagulant treatment was associated with less recurrent ischemic stroke in all age groups. Hemorrhages increased most in the ≥90-year age group, but this did not offset the overall beneficial effect of the anticoagulant. Apart from age, no other cardiovascular risk factor or comorbidity was identified that influenced the risk of anticoagulant-associated hemorrhage. Drugs other than anticoagulants did not influence the incidence of major hemorrhage. CONCLUSIONS: Given the patient characteristics in this study, there is room for more patients to be treated with anticoagulants, without hemorrhages to prevail. In nonagenarians, hemorrhages increased somewhat more, but this did not affect the overall outcome in this age stratum.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Appelros P, Farahmand B, Terént A, et al. To Treat or Not to Treat: Anticoagulants as Secondary Preventives to the Oldest Old With Atrial Fibrillation. Stroke. 2017. PMID: 28487335. doi:10.1161/STROKEAHA.117.016902

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。